コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 en with TAMOF syndrome can have VWF-mediated thrombotic microangiopathy.
2 had been diagnosed with posttransplantation thrombotic microangiopathy.
3 was predominantly from the development of a thrombotic microangiopathy.
4 There were no episodes of thrombotic microangiopathy.
5 dered in patients with transplant-associated thrombotic microangiopathy.
6 hrombocytopenia, hemolytic anemia, and renal thrombotic microangiopathy.
7 luminal deposits, which are classic signs of thrombotic microangiopathy.
8 essing the diagnostic challenge presented by thrombotic microangiopathy.
9 ypertension, proteinuria, renal failure, and thrombotic microangiopathy.
10 a, hemolytic anemia, and AKI with glomerular thrombotic microangiopathy.
11 helium, which may contribute to formation of thrombotic microangiopathy.
12 lytic-uremic syndrome (DHUS), a severe renal thrombotic microangiopathy.
13 ning, chronic disease of complement-mediated thrombotic microangiopathy.
14 ocytopenic purpura (TTP), a life-threatening thrombotic microangiopathy.
15 se resulted in the development of glomerular thrombotic microangiopathy.
16 the diagnosis and treatment of TTP and other thrombotic microangiopathies.
17 o events during pathogenesis of Stx-mediated thrombotic microangiopathies.
18 -the PLASMIC score-to stratify patients with thrombotic microangiopathy according to their risk of ha
19 In group 2 (n = 10), grafts also developed thrombotic microangiopathy affecting mainly the glomerul
21 icient animals developed severe C5-dependent thrombotic microangiopathy after induction of complement
22 mic medical centres in Boston, MA, USA, with thrombotic microangiopathy and a possible diagnosis of t
23 rsus 49 +/- 3 mg/d; P < 0.01); and abrogated thrombotic microangiopathy and decreased plasma aldoster
24 k of TLR2/4 attenuated histone-induced renal thrombotic microangiopathy and glomerular necrosis in mi
25 ation is not required for the development of thrombotic microangiopathy and HUS induced by EHEC Shiga
26 II infusion, proteinuria (17 +/- 9 mg/d) and thrombotic microangiopathy and plasma aldosterone (18 +/
27 Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with signi
28 rrow transplantation/chemotherapy-associated thrombotic microangiopathy, and in the hemolytic-uremic
29 s including tubular swelling, vacuolization, thrombotic microangiopathy, and increased expression of
30 se, is decreased in adults with VWF-mediated thrombotic microangiopathy, and intensive plasma exchang
31 underlying matrix and platelet aggregation, thrombotic microangiopathy, and neutrophilic infiltratio
32 tic events manifested with acute and chronic thrombotic microangiopathy; and (c) EC proinflammatory c
33 tologists alike, classically associated with thrombotic microangiopathy are the hemolytic-uremic synd
34 sufficient to establish posttransplantation thrombotic microangiopathy as a discrete clinical or pat
35 , who are frequently called upon to diagnose thrombotic microangiopathy, be aware of its association
36 ation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (dense de
37 (C, 6%; C3, 1%), associated mainly with late thrombotic microangiopathy (C: 78%; C3: 11% of cases).
39 lytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy caused by complement pathogen
40 ypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy caused by uncontrolled activa
42 purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopa
43 sanguineous family with patients affected by thrombotic microangiopathy characterized by significant
44 hemolytic uremic syndrome (aHUS) is a severe thrombotic microangiopathy characterized by uncontrolled
46 lytic uremic syndrome (aHUS) is a rare renal thrombotic microangiopathy commonly associated with rare
47 For 19 months, the patient had relapsing thrombotic microangiopathy despite plasma exchange; sple
48 ns or by autoantibodies is associated with a thrombotic microangiopathy disease, atypical hemolytic u
49 ring system also more consistently diagnosed thrombotic microangiopathy due to severe ADAMTS13 defici
50 hange in the platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decreas
52 can cause hemolytic-uremic syndrome (HUS), a thrombotic microangiopathy, following infections by Shig
53 ndrome during pregnancy, and implications of thrombotic microangiopathies for subsequent pregnancies
54 registry of the French Reference Center for Thrombotic Microangiopathies from 2000-2010 to identify
55 alternative pathway that are associated with thrombotic microangiopathies, glomerulonephritides, and
57 elated complication, including preeclampsia, thrombotic microangiopathy, heart failure, sepsis, or po
58 pered by the inability to reproduce HUS with thrombotic microangiopathy, hemolytic anemia, and acute
59 arks of hemolytic uremic syndrome, including thrombotic microangiopathy, hemolytic anemia, thrombocyt
60 nsider this newly established mouse model of thrombotic microangiopathy highly predictive for investi
61 alysis of case series of posttransplantation thrombotic microangiopathy illustrates uncertainties reg
66 liorate malignant nephrosclerotic lesions of thrombotic microangiopathy in salt-loaded, stroke-prone,
67 ecome more prominent, such as development of thrombotic microangiopathy in the graft or systemic cons
68 sometimes complicated by a potentially fatal thrombotic microangiopathy in the recipient baboons.
69 erized by marked interstitial hemorrhage and thrombotic microangiopathy in the renal vasculature.
70 enes have been demonstrated to predispose to thrombotic microangiopathies including atypical hemolyti
71 l role for aldosterone in the development of thrombotic microangiopathy, independent of hypertension.
76 nitoring of such pregnancies for episodes of thrombotic microangiopathy is essential but, the best st
77 the development of T3SS-dependent intestinal thrombotic microangiopathy (iTMA) and ischemic enteritis
78 F multimers, as are present in patients with thrombotic microangiopathy, lack an inhibitory effect on
79 proteinuria (78 +/- 7 mg/d) were greater and thrombotic microangiopathy lesions were comparable to SH
80 x glomerulonephritis (n = 3), HIV-associated thrombotic microangiopathy (n = 1), and HIV-negative pat
81 of necroinflammation to AKI is discussed in thrombotic microangiopathies, necrotizing and crescentic
84 ity might prove useful in the future care of thrombotic microangiopathy patients and might be a ratio
86 e in understanding the pathogenesis of other thrombotic microangiopathies, post-HSCT TMA remains poor
88 y appears to be an important risk factor for thrombotic microangiopathy rather than a specific diagno
91 ggest that in DGKE-associated aHUS patients, thrombotic microangiopathy results from impaired EC prol
92 s presented with biopsy-proven de novo renal thrombotic microangiopathy (RTMA), occurring 5 to 120 d
93 or modestly reduced (>20%) in other forms of thrombotic microangiopathy secondary to hematopoietic pr
94 their relative roles in the pathogenesis of thrombotic microangiopathy, SHRSP were adrenalectomized
97 stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-TMA) is not completely un
99 sporadic hemolytic-uremic syndrome (HUS) are thrombotic microangiopathies that occur in the absence o
100 otheliosis" represents a specific variant of thrombotic microangiopathy that is characterized by glom
102 nties about the evaluation and management of thrombotic microangiopathy that occurs following allogen
103 lthough there was no evidence of spontaneous thrombotic microangiopathy, the hepatocyte-specific FH-d
104 ication of patients with posttransplantation thrombotic microangiopathy; these criteria may result in
106 e innate immune system in the development of thrombotic microangiopathy (TM) after alpha1,3-galactosy
107 and marrow transplantation (BMT)-associated thrombotic microangiopathy (TM) contributes to transplan
109 cell chimerism, however, results in a severe thrombotic microangiopathy (TM) that includes pronounced
110 cell chimerism, however, results in a severe thrombotic microangiopathy (TM) that includes pronounced
111 cell chimerism, however, results in a severe thrombotic microangiopathy (TM) that includes vascular i
114 regulation contributes to the development of thrombotic microangiopathy (TMA) after hematopoietic ste
115 emonstration of impaired C regulation in the thrombotic microangiopathy (TMA) atypical hemolytic urem
116 ypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by excess
118 ase reports have described the occurrence of thrombotic microangiopathy (TMA) following IV abuse of e
122 ietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TMA) is a complication that
130 the numerous adverse side effects of FK506, thrombotic microangiopathy (TMA) stands out as an infreq
131 typical hemolytic uremic syndrome, a type of thrombotic microangiopathy (TMA) that causes renal failu
132 l hemolytic uremic syndrome (aHUS) develop a thrombotic microangiopathy (TMA) that in most cases is a
133 glomerular proliferative lesions, glomerular thrombotic microangiopathy (TMA) was found as a common g
134 Rates of veno-occlusive disease (VOD) and thrombotic microangiopathy (TMA) were lower in the nonsi
135 Complement activation has a major role in thrombotic microangiopathy (TMA), a disorder that can oc
136 uncontrolled complement activation, systemic thrombotic microangiopathy (TMA), and vital organ damage
137 ed complement activity, the development of a thrombotic microangiopathy (TMA), and widespread end org
139 ons in fH are associated with a rare form of thrombotic microangiopathy (TMA), known as atypical hemo
140 s developed hemolytic uremic syndrome (HUS), thrombotic microangiopathy (TMA), or HUS-like events, ex
141 iciency virus-2 (HIV-2) strain develop renal thrombotic microangiopathy (TMA), which morphologically
149 istinguishes TTP from HUS and other types of thrombotic microangiopathy (TMA); therefore, the term TT
152 , would be the second hit for development of thrombotic microangiopathies (TMAs), a group of life-thr
157 endothelial growth factor (VEGF) results in thrombotic microangiopathy, we addressed the possibility
159 t is one of a group of conditions termed the thrombotic microangiopathies, which are characterized by
160 croangiopathic hemolytic anemia characterize thrombotic microangiopathy, which includes two major dis
161 The emerging data on the risk of developing thrombotic microangiopathy while on Ticlopidine and the
164 ypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy with severe renal injury seco
165 r renal injury and in particular developed a thrombotic microangiopathy, with mesangiolysis, endothel
166 t lesion associated with graft failure was a thrombotic microangiopathy, with resulting ischemic inju
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。